Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in Initial Cardiac Function, Treatment, and Outcomes in Peripartum Cardiomyopathy.

The journal of obstetrics and gynaecology research·2026
Same author

AMI-SSS01 portable phonocardiographic examination with AI-assisted assessment for detecting heart failure exacerbations in home-based medical care in Japanese primary care clinics: a study protocol for a randomised controlled feasibility trial.

BMJ open·2026
Same author

Characteristics and Outcomes of Multisystemic Inflammation in Patients Clinically Diagnosed With Non-COVID-19-Related Fulminant Myocarditis.

Circulation reports·2026
Same author

Papillary fibroelastoma arising in the left ventricular septum causing left ventricular outflow tract stenosis.

Journal of medical ultrasonics (2001)·2026
Same author

Association Between Severe Aortic Stenosis and Amyloid Deposition in the Myocardium of Patients With Wild-Type Transthyretin Cardiac Amyloidosis.

Circulation reports·2026
Same author

Effect of Empagliflozin on Device-Measured Thoracic Impedance in Patients With Type 2 Diabetes Treated With an Implantable Cardioverter Defibrillator.

Circulation·2026
Same journal

Mast Cells and Cardiovascular Disorders.

Current vascular pharmacology·2026
Same journal

Occupational and Environment-Related Cardiovascular Disease: A Comprehensive Review of the Literature.

Current vascular pharmacology·2026
Same journal

Metalloproteinases 2 and 9 as Biomarkers in Acute Elevation of Blood Pressure.

Current vascular pharmacology·2026
Same journal

Is the Cardiovascular Risk Increased in Patients with Isolated Systolic Hypertension and Anemia?

Current vascular pharmacology·2026
Same journal

Periodontal Disease and Cardiovascular Risk Factors.

Current vascular pharmacology·2026
Same journal

The Use of Colchicine in Cardiovascular Disease: Anti-Inflammatory Mechanisms and Clinical Utility.

Current vascular pharmacology·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Ezetimibe and vascular endothelial function.

Satoshi Ikeda1, Koji Maemura

  • 1Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.

Current Vascular Pharmacology
|November 4, 2010
PubMed
Summary
This summary is machine-generated.

Ezetimibe, a cholesterol absorption inhibitor, may help manage hypercholesterolemia when statins are insufficient. Combined therapy might slow atherosclerosis, but its impact on cardiovascular events requires further study.

Related Experiment Videos

Last Updated: Jun 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiology
  • Pharmacology
  • Atherosclerosis Research

Background:

  • Hypercholesterolemia is a significant cardiovascular disease risk factor.
  • Statins effectively lower LDL-C but often fail to meet treatment goals in high-risk patients.
  • Ezetimibe inhibits intestinal cholesterol absorption, reducing LDL-C, especially with statins.

Purpose of the Study:

  • To review ezetimibe's effects on cardiovascular diseases, focusing on vascular endothelial function.
  • To explore the potential synergistic anti-atherosclerotic effects of combined statin and ezetimibe therapy.
  • To investigate the mechanisms underlying ezetimibe's anti-atherosclerotic actions.

Main Methods:

  • Literature review of studies on ezetimibe and cardiovascular disease.
  • Analysis of ezetimibe's impact on vascular endothelial function.
  • Evaluation of combined statin-ezetimibe therapy in hypercholesterolemia.

Main Results:

  • Ezetimibe reduces LDL-C levels, particularly when used with statins.
  • Combined statin-ezetimibe therapy may offer additive benefits in retarding atherogenesis.
  • Vascular endothelial function is a key area influenced by lipid-lowering interventions.

Conclusions:

  • Combined inhibition of cholesterol synthesis and absorption may slow the atherogenetic process.
  • Lipid-lowering effects are considered the primary mechanism, but non-lipid effects warrant further investigation.
  • Ezetimibe's direct impact on atherogenesis independent of lipid reduction needs elucidation.